Q-omics provides the consensus-scored SUPT5H profile across patient tissues and cancer cell-line models. SUPT5H expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SUPT5H is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, SUPT5H protein abundance shows 27,820 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where SUPT5H shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUPT5H — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUPT5H survival associations across molecular data types. SUPT5H RNA expression shows survival associations in the most cancer types (29), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUPT5H RNA expression–survival associations across cancer types. High SUPT5H expression shows unfavorable associations in MESO, ACC, LIHC, KIRP and OV, but favorable associations in CHOL. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SUPT5H RNA expression.
This table summarizes SUPT5H tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SUPT5H. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUPT5H shows higher tumor expression in HNSC, KIRC, COAD, LIHC, LUAD and STAD. The HNSC box plot shows higher SUPT5H RNA expression in tumor versus normal tissue (log2 FC = +0.741, t-test p < 0.001).
This table shows molecular features associated with SUPT5H in patient tissues and cancer cell lines. In patient samples, SUPT5H shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SUPT5H RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
